Dormant hair follicles will be more effectively revitalized with nutrients and therapeutics delivered quickly and powerfully through extremely fine droplet sizes produced from proprietary UST nanoemulsion technology.
SOUTH EASTON, MA / ACCESSWIRE / Oct 26, 2022 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leading developer and marketer of broad-capacity specialized pressure-based instruments, consumables and testing services to the global cosmetics, nutraceuticals, biotherapeutics industries and food. beverage industries, among others, today confirmed specific product launch plans agreed upon in their extensive partnership with science-driven skin care industry leader Dr. Denese SkinScience, which were recently shared on the show sponsored by FORCE Family Office Development of a new generation of skin care products webinar (PBIO/Dr. Denese FORCE Webinar 101322). Highlighting Dr. Denese’s world-renowned expertise and long-established leadership role as an innovator in skin care, the webinar revealed that the two companies had chosen three additives/areas for their initial collaborative development of new and valuable lines of skincare products, all of which would harness the benefits of PBI’s patented UST nanoemulsification process: (i) retinol, (ii) lipid-soluble vitamin C, and (iii) hair loss prevention/ Hair growth.
Dr. Adrienne Denese, MD, Ph.D. a world-renowned skin care visionary, anti-aging pioneer and president of Dr. Denese SkinScience, explained, “The fundamental challenge in cosmeceuticals and skin care products is to deliver our scientifically engineered payloads of critical nutrients and therapeutic ingredients from quickly, completely, and precisely while penetrating through the skin’s difficult resistive barrier to the living dermal tissues beneath it Many of these key ingredients are “oily” or lipophilic molecules that do not normally mix well with the making it difficult to effectively deliver it for uptake by the water-based biochemistry of human bodies Revolutionary advancement of PBI’s industrially scalable UST platform technology for making nanoemulsions of extremely fine nanodroplet sizes, which are then stable and can deliver nutrients and therapeutic loads with an efficacy without pr history, it is without a doubt one of the most important scientific and process advances for our industry in my lifetime”.
Dr. Denese continued, “Of my patients and clients, the single most requested addition to our product line is an effective intervention for hair loss and hair regrowth, and it is considered much more urgent in related hair loss. with age for women, beyond the enormous demand among men We believe that the challenge of truly effective delivery of stimulation and revitalization to weakened and dormant hair follicles will finally be overcome with the entry of UST nanoemulsion platform technology PBI, and now we are planning to deliver an effective solution to that challenge. In just a few weeks since I made this decision, my team and I have made great progress in developing our first line of products for the prevention of hair loss/hair restoration With the progress to date, we are now aiming to launch the first products in this n Exciting new line of products in time for the 2023 holiday shopping season. What a gift this would be to our current and loyal base of over 500,000 QV C-Customers and many more eager new shoppers!”
Gary Smejkal, Senior Scientist at PBI, said: “We have also recently made wonderful progress in the development of UST-processed retinol and lipid-soluble vitamin C. These very high-quality nanoemulsions consist of oil droplets that are consistent and extremely small. At about 50 nanometers, they are much smaller than the wavelength of visible light, making them highly transparent They are also expected to be stable and effectively soluble in water These starting nutrients and therapeutic nanoemulsion ingredients must be readily available to Dr. Denese SkinScience for inclusion in their skincare products by mid-2023.”
Richard T. Schumacher, President and CEO of PBI, summed up the progress: “We believe that PBI’s lipid-soluble vitamin C and UST nanoemulsified retinol-enhanced products will add valuable new dimensions to multiple Dr. Denese SkinScience products beginning in mid-2019. 2023. The most exciting thing is that it now appears that the new line of hair loss prevention/hair restoration products should be ready for commercialization in about a year, which means that these products could add millions in revenue to PBI results for 2023. This would be in addition to the approximately $5 million in revenue that we believe will be received in 2023 from the completion of the three new nano-CBD contracts that have been announced in recent months and that we expect complete in 2023, with shipments starting in the first quarter of next year.
Mr. Schumacher concluded, “Dr. Adrienne Denese is a titan in the worldwide cosmeceutical/skincare industry and has amassed sales of over $500 million through QVC alone. Her mission in life has been helping women look and feel younger and live healthier lives. She has relentlessly focused on the science, quality, potency and efficacy of her products above all else. We feel immensely privileged having earned their support and close partnership between our companies. These are truly exciting times for all PBIO stakeholders.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for life sciences and other industries worldwide. Our products are based on the unique properties of both constant (ie static) and alternating (ie Pressure Cycling Technology or PCT) hydrostatic pressure. PCT is a proprietary enabling technology platform that uses alternating hydrostatic pressure cycling between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (eg, cell lysis, biomolecule extraction). Our primary focus is on developing PCT-based products for biomarker and target discovery, drug design and development, biotherapeutic characterization and quality control, soil and plant biology, forensics, and anti-bioterrorist applications. In addition, significant new market opportunities have arisen in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired proprietary technology from BaroFold, Inc. (the “BaroFold” technology) to enable entry in the biopharmaceutical contract services sector, and (2) the use of our newly patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create fluid-stable nanoemulsions that would otherwise would otherwise be immiscible (e.g., oils and water) and to (ii) prepare high-quality, homogenized, long-shelf-life or room-stable, low-acid liquid foods that cannot be effectively preserved using conventional technologies. non-thermal existing.
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any results, level of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “would”, “expects”, “plans”, “intends”, “anticipates” “believes”. “, estimates, “predicts”, “projects”, “potential” or “continues” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider several factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statements. These risks, uncertainties, and other factors include, among others, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and other reports filed by the Company from time to time with the latter. The Company undertakes no obligation to update the information contained in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link: http://www.pressionbiosciences.com
Visit us on Facebook, LinkedIn and Twitter.
Richard T. Schumacher, President and CEO (508) 230-1828 (T)
John B. Hollister, Director of Sales and Marketing (805) 908-5719 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 703-8557 (T)
Adrienne Denese, MD, Ph.D., President of Dr. Denese SkinScience (888) 220-0303 (T)
FONT: Pressure BioSciences Inc.
See the source version at accesswire.com: